Abbvie Inc Stock Price, News & Analysis

AbbVie (NYSE:ABBV) has submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel once-daily oral treatment for Parkinson's disease. The submission is supported by positive results from the Phase 3 TEMPO clinical program, which demonstrated significant efficacy across multiple trials.

The TEMPO program included three Phase 3 trials: TEMPO-1 and TEMPO-2 showed statistically significant improvement in MDS-UPDRS Parts II and III scores in early Parkinson's patients, while TEMPO-3 demonstrated increased "on" time in patients using tavapadon as an adjunctive therapy to levodopa. The submission also includes interim data from the TEMPO-4 open-label extension trial.

Allergan Aesthetics (NYSE:ABBV) will showcase its new AA Signature™ multimodal treatment approach at the AMWC Dubai conference from October 1-3, 2025. The approach, already successfully launched in 25 countries, addresses different patient needs including Lift Up, Distinct Definition, and skin quality improvement.

The company will host two major symposiums: an AMI symposium featuring Dr. Mauricio de Maio demonstrating live injections, and a Global Medical Affairs symposium focused on skin quality multimodal mastery. Additionally, 7 e-posters presenting new clinical data will be featured at the conference, covering topics from personalized aesthetics to skin quality treatments.

Allergan Aesthetics (NYSE:ABBV) announced the expansion of SKINVIVE by JUVÉDERM® into 35 additional markets, bringing the total to 57 global markets in 2025. SKINVIVE® is positioned as the market's longest-lasting hydrating injectable, delivered in a single treatment.

The expansion aligns with growing market demand, as research shows 94% of people desire improved facial skin quality. The global skin quality market is valued at $5.2B, with consumers increasingly prioritizing skin health and natural-looking results. The company's AA Signature™ holistic approach has already launched in 25 countries, supporting this strategic expansion.

The announcement coincides with upcoming presentations at the Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai on October 1, where experts will discuss integrated aesthetic modalities for skin quality improvement.

AbbVie's (NYSE:ABBV) subsidiary Allergan Aesthetics has launched its largest-ever marketing campaign for BOTOX® Cosmetic titled 'The One & Only.' The campaign showcases real patients and their unique stories across multiple media channels including TV, digital, and out-of-home advertising.

As the #1 selling neurotoxin worldwide, BOTOX® Cosmetic has achieved significant milestones with over 100 million vials sold globally and maintains the most FDA-approved aesthetic indication areas in its category. Market research indicates strong customer satisfaction, with 77% of treated consumers considering it worth the cost and 91% of patients expressing intent to continue treatment.

The product recently received recognition as 'Best Injectable' in the 2025 Cosmopolitan Readers' Choice Beauty Awards and continues to be the most trusted choice among aesthetic providers, with 95% of specialists choosing it for themselves, friends, and family.

AbbVie (NYSE:ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to stockholders of record as of October 15, 2025. The company has demonstrated strong commitment to shareholder returns, increasing its dividend by 310 percent since its inception in 2013.

As a member of the S&P Dividend Aristocrats Index, AbbVie has maintained a track record of consistently increasing its dividend for at least 25 consecutive years, highlighting its financial stability and dedication to shareholder value.

AbbVie (NYSE:ABBV) announced updated results from the Phase 2 EPCORE® NHL-6 trial evaluating epcoritamab, a subcutaneously administered T-cell engaging bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

The study demonstrated promising results with 92% of patients successfully monitored in outpatient settings. Key findings include low-grade cytokine release syndrome in 40.2% of patients and immune cell-associated neurotoxicity syndrome in 7.6% of patients, with all events resolving without treatment discontinuation.

The trial showed strong efficacy with an overall response rate of 64.3% and complete response rate of 47.6% in patients after one prior therapy line. For patients with two or more prior treatments, response rates were 60.0% and 38.0% respectively.

Allergan Aesthetics (NYSE:ABBV) has launched the "Naturally You with Injectable Hyaluronic Acid Fillers" campaign to provide educational resources about HA injectable fillers. The initiative centers around a comprehensive report available at naturallyyouwithHA.com, which reveals that 90% of consumers are satisfied with HA filler outcomes, and 78% strongly agree that people today prefer natural-looking results.

The report, part of the Aesthetics Evolution Report Series, combines research from consumer and business media, cultural conversations, and proprietary data from Allergan Aesthetics. Key findings show that over 75% of consumers believe HA filler usage will increase, while more than two-thirds use social media for filler education. The campaign includes partnerships with healthcare providers and influencers to promote education and natural-looking outcomes.

AbbVie (NYSE: ABBV) has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference scheduled for Tuesday, September 9, 2025. The company's management will engage in a fireside chat presentation at 9:00 a.m. Central time.

Investors can access the presentation through a live audio webcast on AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available later the same day.

AbbVie (NYSE:ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead asset bretisilocin (GM-2505), a novel psychedelic compound in Phase 2 development for major depressive disorder (MDD), for up to $1.2 billion in upfront and milestone payments.

The Phase 2a study demonstrated significant results, with bretisilocin showing a -21.6 point reduction in MADRS depression score versus -12.1 points for the comparator. The compound features a shorter duration of psychoactive experience while maintaining extended therapeutic benefits, addressing key limitations of existing psychedelic treatments.

As part of the deal, Gilgamesh will spin off into Gilgamesh Pharma Inc., retaining its employees and other programs, including its existing collaboration with AbbVie from 2024.